Menu

Antonin SCHMITT

Dijon

En résumé

Mes compétences :
Pharmacologie
Pharmacocinétique
Pharmacie Clinique
Modelisation PK/PD

Entreprises

  • Université de Bourgogne - MCU-PH (Associate Professor) en Pharmacologie/Pharmacien Hospitalier

    Dijon 2015 - maintenant - Co-director of the speciality Industry at the Faculty of Pharmacy
    - Clinical Pharmacist at the Centre Georges-Francois Leclerc (Dijon's Cancer Institute): expert in the therapeutic use of medications; routinely provide medication therapy evaluations and recommendations to patients and other health care professionals; primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications
    - Lectures in Clinical Pharmacy, Pharmacology and Pharmacokinetics
  • Centre Georges-François Leclerc - Université de Bourgogne - Assistant Hospitalo-Universitaire

    2012 - 2015 - Co-director of the speciality Industry at the Faculty of Pharmacy
    - Clinical Pharmacist at the Centre Georges-Francois Leclerc (Dijon's Cancer Institute): expert in the therapeutic use of medications; routinely provide medication therapy evaluations and recommendations to patients and other health care professionals; primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications
    - Lectures in Clinical Pharmacy, Pharmacology and Pharmacokinetics
  • Novartis - Pharmacocineticien Senior

    RUEIL MALMAISON 2011 - 2012 Clinical Pharmacology representative (CPR) in teams at project level, clinical team level and study level for several projects from Phase I to Phase III.
    CPR for Phase I FIM studies
    Design of concept protocols, development of full clinical protocols, implementation of the studies, analysis (as applicable), interpretation of data (and communication to management/partners), report writing
    Contribution as CPR to all study-related documents (e.g. CRFs, regulatory documents etc.)
    Involvement in multi-site, multi-country Phase II / III studies as CPR, in particular in relation to implementation of appropriate PK sampling for population PK and PK/PD analyses
    Main experience in oncology
    Regulatory experience: preparation of regulatory documents (IB, IMPD) and documents for regulatory consultation (Type C meeting)
  • Novartis - Postdoc en pharmacologie clinique oncologique

    RUEIL MALMAISON 2010 - 2011 Mise au point d'un modèle de pharmacocinétique de population permettant de décrire un phénomène de compétition de la liaison aux protéines plasmatiques entre une molécule mère et ses deux principaux métabolites.
  • Institut Claudius-Regaud - Doctorant en pharmacocinetique

    2008 - 2010 Détermination des caractéristiques des patients impliquées dans les toxicités hématologiques consécutives à l'administration de médicaments anticancéreux : apport de la méthodologie de pharmacocinétique/pharmacodynamique de population. Sous la direction d'Étienne Chatelut et de Didier Concordet
  • Université Paul Sabatier - Faculté de Pharmacie - Moniteur de l'Enseignement Supérieur

    2008 - 2010 Enseignant en pharmacologie et pharmacocinétique
  • CHU de Toulouse - Interne en pharmacie spécialisée

    2006 - 2010

Formations

Réseau